Mast cell-pain connection in eosinophilic esophagitis

TY - JOUR

T1 - Mast cell-pain connection in eosinophilic esophagitis

AU - the Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR) Investigators Group

AU - Zhang, Simin

AU - Shoda, Tetsuo

AU - Aceves, Seema S.

AU - Arva, Nicoleta C.

AU - Chehade, Mirna

AU - Collins, Margaret H.

AU - Dellon, Evan S.

AU - Falk, Gary W.

AU - Gonsalves, Nirmala

AU - Gupta, Sandeep K.

AU - Hirano, Ikuo

AU - Khoury, Paneez

AU - Leung, John

AU - Spergel, Amanda K.Rudman

AU - Spergel, Jonathan M.

AU - Wechsler, Joshua B.

AU - Yang, Guang Yu

AU - Furuta, Glenn T.

AU - Rothenberg, Marc E.

N1 - Funding Information: This study was supported by NIH grant K99/R00 AI158660 (to T.S.) and CEGIR (U54 AI117804), which is part of the Rare Diseases Clinical Research Network (RDCRN), an initiative of the Office of Rare Diseases Research (ORDR), National Center for Advancing Translational Sciences (NCATS), and is co‐funded by the National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NCATS, and in part by the Division of Intramural Research, NIAID/NIH. CEGIR is also supported by patient advocacy groups, including the American Partnership for Eosinophilic Disorders (APFED), Campaign Urging Research for Eosinophilic Disease (CURED), and Eosinophilic Family Coalition (EFC). As a member of the RDCRN, CEGIR is also supported by its Data Management and Coordinating Center (DMCC) (U2CTR002818). Funding Information: M.E.R. is a consultant for Pulm One, Spoon Guru, Allakos, ClostraBio, Serpin Pharm, Celgene, Shire, AstraZeneca, GlaxoSmithKline, Allakos, Adare, Regeneron, and Novartis and has an equity interest in the first five, as well as royalties from reslizumab (Teva Pharmaceuticals) and UpToDate. M.E.R. is an inventor of patents owned by Cincinnati Children's Hospital Medical Center. T.S. has funding from the NIH and is a co‐inventor of patents owned by Cincinnati Children's Hospital Medical Center. M.H.C. is a consultant for Alimentiv (formerly Robarts Clinical Trials, Inc), Allakos, Arena, AstraZeneca, Calypso, Esocap, GlaxoSmithKline, Receptos/Celgene/BMC, Regeneron, and Takeda and received research funds from Receptos/Celgene/BMC, Regeneron, and Takeda. J.B.W. is a consultant for Allakos, Regeneron, Sanofi/Genzyme, AstraZeneca, and InveniAI and received clinical trial support from Allakos and Regeneron. S.K.G. is a consultant for Abbott, Adare, Allakos, Celgene, Gossamer Bio, QOL, UpToDate, Medscape, and Viaskin and received research support from Shire, Allakos, Adare, and CEGIR (NIH U54 AI117804). J.M.S. has funding from the NIH, Regeneron, Sanofi, Novartis, and FARE; is a consultant for Regeneron, Allakos, Sanofi, Novartis, and Takeda; and is an author for UpToDate. S.A.A. has funding from NIH and is an educational speaker for MedScape and Sanofi‐Regeneron, a consultant for AstraZeneca, and an author for UpToDate. M.C. received consulting fees from Regeneron, Allakos, Adare/Ellodi, Shire/Takeda, AstraZeneca, Sanofi, and Bristol Myers Squibb and received research funding from Regeneron, Allakos, Shire/Takeda, AstraZeneca, Adare/Ellodi, and Danone. E.S.D. received research funding from Adare/Ellodi, Allakos, Arena, AstraZeneca, GSK, Meritage, Miraca, Nutricia, Celgene/Receptos/BMS, Regeneron, and Shire/Takeda; received consulting fees from Abbott, Abbvie, Adare/ Ellodi, Aimmune, Allakos, Amgen, Arena, AstraZeneca, Avir, Biorasi, Calypso, Celgene/Receptos/BMS, Celldex, Eli Lilly, EsoCap, GSK, Gossamer Bio, Landos, Morphic, Nutricia, Parexel/Calyx, Phathom, Regeneron, Revolo, Robarts/Alimentiv, Salix, Sanofi, and Shire/Takeda; and received educational grants from Allakos, Banner, and Holoclara. A.K.R.S.'s co‐authorship of this publication does not necessarily constitute endorsement by the National Institute of Allergy and Infectious Diseases, the National Institutes of Health or any other agency of the United States government. S.Z. has no relevant conflicts of interest. I.H. received research funding from Adare/Ellodi, Allakos, Arena, AstraZeneca, Meritage, Celgene/Receptos/BMS, Regeneron/Sanofi, and Shire/Takeda; received consulting fees from Adare/Ellodi, Allakos, Amgen, Arena, AstraZeneca, Celgene/Receptos/BMS, Eli Lilly, EsoCap, Gossamer Bio, Parexel/Calyx, Phathom, Regeneron, Sanofi, and Shire/Takeda; and is an educational speaker for MedScape and Sanofi‐Regeneron. Funding Information: We thank the Confocal Imaging Core at CCHMC for their support and expertise. Funding information This study was supported by NIH grant K99/R00 AI158660 (to T.S.) and CEGIR (U54 AI117804), which is part of the Rare Diseases Clinical Research Network (RDCRN), an initiative of the Office of Rare Diseases Research (ORDR), National Center for Advancing Translational Sciences (NCATS), and is co-funded by the National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NCATS, and in part by the Division of Intramural Research, NIAID/NIH. CEGIR is also supported by patient advocacy groups, including the American Partnership for Eosinophilic Disorders (APFED), Campaign Urging Research for Eosinophilic Disease (CURED), and Eosinophilic Family Coalition (EFC). As a member of the RDCRN, CEGIR is also supported by its Data Management and Coordinating Center (DMCC) (U2CTR002818).

PY - 2022/6

Y1 - 2022/6

UR - http://www.scopus.com/inward/record.url?scp=85127668807&partnerID=8YFLogxK

U2 - 10.1111/all.15260

DO - 10.1111/all.15260

M3 - Letter

C2 - 35175645

AN - SCOPUS:85127668807

SN - 0105-4538

VL - 77

SP - 1895

EP - 1899

JO - Allergy: European Journal of Allergy and Clinical Immunology

JF - Allergy: European Journal of Allergy and Clinical Immunology

IS - 6

ER -